File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer

TitleAAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer
Authors
Nie, BShen, ZWen, JBWong, OGWHsueh, WDHuo, LFKung, HFJiang, BLin, MCM
Issue Date2008
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/
Citation
Molecular Cancer Therapeutics, 2008, v. 7 n. 9, p. 2855-2865 How to Cite?
DOI: http://dx.doi.org/10.1158/1535-7163.MCT-08-0366
AbstractThis study tried to evaluate the application of a novel cancer gene therapy using recombinant adeno-associated virus (AAV) carrying the kringle 1 domain of human hepatocyte growth factor (AAV-HGFK1) in combination with recombinant adenovirus carrying p53 gene (Ad-p53). BALB/c and nude mice models of colon cancer were established and the mice were treated with AAV-HGFK1 alone or in combination with Ad-p53. Combination of AAV-HGFK1 and Ad-p53 significantly prolonged the survival of the mice and also significantly inhibited primary and secondary tumor growth. Histochemical examination of the tumors revealed that AAV-HGFK1+Ad-p53 combinatorial treatment not only induced necrosis and apoptosis in the tumors but also suppressed tumor angiogenesis. The antiangiogenesis effect could likely be attributed to the ability of AAV-HGFK1+Ad-p53 viral cocktail to inhibit endothelial cell migration and proliferation. AAV-HGFK1+Ad-p53 also inhibited tumor cell growth in vitro by inhibiting epidermal growth factor receptor phosphorylation. Therefore, AAV-HGFK1+Ad-p53 cocktail therapy has a significantly higher therapeutic effect than AAV-HGFK1 or Ad-p53 alone and is a novel promising gene therapy for colon cancer. Copyright © 2008 American Association for Cancer Research.
Persistent Identifierhttp://hdl.handle.net/10722/58386
ISSN
1535-7163
2021 Impact Factor: 6.009
2020 SCImago Journal Rankings: 2.717
ISI Accession Number ID
WOS:000259387300027
Funding AgencyGrant Number
Hong Kong Special Administrative Region, ChinaITS/084/03
RGC HKU7705/07M
Funding Information:

Innovation and Technology Commission of the Hong Kong Special Administrative Region, China, ITS/084/03 (M.C.M. Lin) and RGC HKU7705/07M (M.C.M. Lin).

References
References in Scopus
Grants
Development of Novel AAV based anti-angiogenesis gene therapy for the treatment of liver cancer

 

DC FieldValueLanguage
dc.contributor.authorNie, Ben_HK
dc.contributor.authorShen, Zen_HK
dc.contributor.authorWen, JBen_HK
dc.contributor.authorWong, OGWen_HK
dc.contributor.authorHsueh, WDen_HK
dc.contributor.authorHuo, LFen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorJiang, Ben_HK
dc.contributor.authorLin, MCMen_HK
dc.date.accessioned2010-05-31T03:29:23Z-
dc.date.available2010-05-31T03:29:23Z-
dc.date.issued2008en_HK
dc.identifier.citationMolecular Cancer Therapeutics, 2008, v. 7 n. 9, p. 2855-2865en_HK
dc.identifier.issn1535-7163en_HK
dc.identifier.urihttp://hdl.handle.net/10722/58386-
dc.description.abstractThis study tried to evaluate the application of a novel cancer gene therapy using recombinant adeno-associated virus (AAV) carrying the kringle 1 domain of human hepatocyte growth factor (AAV-HGFK1) in combination with recombinant adenovirus carrying p53 gene (Ad-p53). BALB/c and nude mice models of colon cancer were established and the mice were treated with AAV-HGFK1 alone or in combination with Ad-p53. Combination of AAV-HGFK1 and Ad-p53 significantly prolonged the survival of the mice and also significantly inhibited primary and secondary tumor growth. Histochemical examination of the tumors revealed that AAV-HGFK1+Ad-p53 combinatorial treatment not only induced necrosis and apoptosis in the tumors but also suppressed tumor angiogenesis. The antiangiogenesis effect could likely be attributed to the ability of AAV-HGFK1+Ad-p53 viral cocktail to inhibit endothelial cell migration and proliferation. AAV-HGFK1+Ad-p53 also inhibited tumor cell growth in vitro by inhibiting epidermal growth factor receptor phosphorylation. Therefore, AAV-HGFK1+Ad-p53 cocktail therapy has a significantly higher therapeutic effect than AAV-HGFK1 or Ad-p53 alone and is a novel promising gene therapy for colon cancer. Copyright © 2008 American Association for Cancer Research.en_HK
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/en_HK
dc.relation.ispartofMolecular Cancer Therapeuticsen_HK
dc.titleAAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1535-7163&volume=7&spage=2855&epage=2865&date=2008&atitle=AAV-HGFK1+and+Ad-p53+Cocktail+Therapy+Prolongs+Survival+of+Mice+with+Colon+Canceren_HK
dc.identifier.emailLin, MCM:mcllin@hkucc.hku.hken_HK
dc.identifier.authorityLin, MCM=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1535-7163.MCT-08-0366en_HK
dc.identifier.pmid18790766en_HK
dc.identifier.scopuseid_2-s2.0-54049136956en_HK
dc.identifier.hkuros151301en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-54049136956&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume7en_HK
dc.identifier.issue9en_HK
dc.identifier.spage2855en_HK
dc.identifier.epage2865en_HK
dc.identifier.isiWOS:000259387300027-
dc.publisher.placeUnited Statesen_HK
dc.relation.projectDevelopment of Novel AAV based anti-angiogenesis gene therapy for the treatment of liver cancer-
dc.identifier.scopusauthoridNie, B=36103082600en_HK
dc.identifier.scopusauthoridShen, Z=35759640300en_HK
dc.identifier.scopusauthoridWen, JB=36853898300en_HK
dc.identifier.scopusauthoridWong, OGW=7004813981en_HK
dc.identifier.scopusauthoridHsueh, WD=40161565600en_HK
dc.identifier.scopusauthoridHuo, LF=9275343500en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridJiang, B=34770534200en_HK
dc.identifier.scopusauthoridLin, MCM=7404816359en_HK
dc.identifier.issnl1535-7163-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats